Published in Neurochem Int on July 22, 2007
Dopamine release in the basal ganglia. Neuroscience (2011) 1.67
Regulation of striatal dopamine release by presynaptic auto- and heteroreceptors. Basal Ganglia (2012) 0.92
The endocannabinoid 2-arachidonoylglycerol mediates D1 and D2 receptor cooperative enhancement of rat nucleus accumbens core neuron firing. Neuroscience (2011) 0.90
Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2. Neurochem Int (2008) 0.88
Endocannabinoid-dopamine interactions in striatal synaptic plasticity. Front Pharmacol (2012) 0.85
The endogenous cannabinoid, anandamide, inhibits dopamine transporter function by a receptor-independent mechanism. J Neurochem (2009) 0.85
Cannabinoids in the management of spasticity associated with multiple sclerosis. Neuropsychiatr Dis Treat (2008) 0.83
Classification of H₂O₂as a neuromodulator that regulates striatal dopamine release on a subsecond time scale. ACS Chem Neurosci (2012) 0.80
Striatal dopamine neurotransmission: regulation of release and uptake. Basal Ganglia (2016) 0.79
ROS produced by NOX2 control in vitro development of cerebellar granule neurons development. ASN Neuro (2015) 0.79
A Role for Adenosine A1 Receptors in GABA and NMDA-Receptor Mediated Modulation of Dopamine Release: Studies Using Fast Cyclic Voltammetry. Sensors (Basel) (2008) 0.75
Endocannabinoid modulation of dopamine neurotransmission. Neuropharmacology (2017) 0.75
The functional anatomy of basal ganglia disorders. Trends Neurosci (1989) 12.28
Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci (1991) 5.88
Putting a spin on the dorsal-ventral divide of the striatum. Trends Neurosci (2004) 5.55
Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A (1990) 5.48
Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 5.12
Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature (2007) 4.36
Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci (1999) 3.57
Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat Neurosci (2002) 3.34
Nicotine amplifies reward-related dopamine signals in striatum. Nat Neurosci (2004) 3.20
Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci (1999) 2.92
Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum. Nat Neurosci (2001) 2.69
Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res (2006) 2.62
Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. J Neurosci (2007) 2.32
Frequency-dependent modulation of dopamine release by nicotine. Nat Neurosci (2004) 2.32
Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. J Neurosci (2005) 2.18
Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J Neurosci (2004) 2.10
Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacology (2002) 1.75
Disruption of endocannabinoid release and striatal long-term depression by postsynaptic blockade of endocannabinoid membrane transport. J Neurosci (2004) 1.74
Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology (2004) 1.73
Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res (1991) 1.67
Inhibition of dopamine release via presynaptic D2 receptors: time course and functional characteristics in vivo. J Neurosci (2001) 1.66
CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol (2001) 1.63
Activation of ATP-sensitive K+ (K(ATP)) channels by H2O2 underlies glutamate-dependent inhibition of striatal dopamine release. Proc Natl Acad Sci U S A (2003) 1.41
Biphasic effects of anandamide. Pharmacol Biochem Behav (1998) 1.41
Nitric oxide: a novel link between synaptic and nonsynaptic transmission. Trends Neurosci (2001) 1.40
Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. Synapse (2000) 1.38
Glutamate-dependent inhibition of dopamine release in striatum is mediated by a new diffusible messenger, H2O2. J Neurosci (2003) 1.33
Novel Ca2+ dependence and time course of somatodendritic dopamine release: substantia nigra versus striatum. J Neurosci (2001) 1.33
The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol (2003) 1.30
N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol Pharmacol (2002) 1.28
Role of high-affinity receptors and membrane transporters in nonsynaptic communication and drug action in the central nervous system. Pharmacol Rev (2000) 1.26
Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. J Neurosci (2005) 1.26
Characteristics of electrically evoked somatodendritic dopamine release in substantia nigra and ventral tegmental area in vitro. J Neurophysiol (1997) 1.22
Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. J Physiol (2001) 1.22
Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. Neuroscience (1998) 1.21
Induction of striatal long-term synaptic depression by moderate frequency activation of cortical afferents in rat. J Physiol (2004) 1.20
Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience (2005) 1.18
Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. Eur J Neurosci (2003) 1.16
Activational role of cannabinoids on movement. Eur J Pharmacol (2000) 1.08
Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. J Neurochem (1997) 1.07
Analysis of the effects of cannabinoids on identified synaptic connections in the caudate-putamen by paired recordings in transgenic mice. J Physiol (2006) 1.04
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology (2001) 1.03
Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia. Neuroscience (2003) 1.03
Subcellular and subsynaptic distribution of the NR1 subunit of the NMDA receptor in the neostriatum and globus pallidus of the rat: co-localization at synapses with the GluR2/3 subunit of the AMPA receptor. Eur J Neurosci (1998) 1.02
Endocannabinoids restrict hippocampal long-term potentiation via CB1. Neuropharmacology (2005) 1.01
Evidence for the preferential localization of glutamate receptor-1 subunits of AMPA receptors to the dendritic spines of medium spiny neurons in rat striatum. Neuroscience (1998) 0.99
Immunolocalization of CB1 receptor in rat striatal neurons: a confocal microscopy study. Synapse (2004) 0.96
Neuromorphological background of cannabis addiction. Brain Res Bull (2003) 0.96
Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry (2003) 0.95
Synaptic localization of GABA(A) receptor subunits in the striatum of the rat. J Comp Neurol (2000) 0.95
Presynaptic regulation of dopamine release in corpus striatum monitored in vitro in real time by fast cyclic voltammetry. Brain Res (1990) 0.95
CB1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum. J Neurochem (2007) 0.95
H2O2 signaling in the nigrostriatal dopamine pathway via ATP-sensitive potassium channels: issues and answers. Antioxid Redox Signal (2007) 0.94
Effects of cannabinoids on dopamine release in the corpus striatum and the nucleus accumbens in vitro. J Neurochem (1999) 0.93
An acute dose of delta 9-tetrahydrocannabinol affects behavioral and neurochemical indices of mesolimbic dopaminergic activity. Behav Brain Res (1993) 0.90
Improved methods for construction of carbon fibre electrodes for extracellular spike recording. J Neurosci Methods (2001) 0.86
Inhibitory effect of nitric oxide on dopamine transporters: interneuronal communication without receptors. Neurochem Int (2004) 0.86
Localization of cannabinoid receptor in the human developing and adult basal ganglia. Higher levels in the striatonigral neurons. Neurosci Lett (1992) 0.85
Cannabinoids decrease corticostriatal synaptic transmission via an effect on glutamate uptake. J Neurosci (2003) 0.85
Survey on cannabis use in Parkinson's disease: subjective improvement of motor symptoms. Mov Disord (2004) 0.85
Neurobehavioral effects of delta 9-THC and cannabinoid (CB1) receptor gene expression in mice. Behav Brain Res (1995) 0.84
A possible role of nitric oxide in the regulation of dopamine transporter function in the striatum. Neurochem Int (1999) 0.84
Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease. Mov Disord (2003) 0.82
Catalepsy induced by intrastriatal injections of delta9-THC and 11-OH-delta9-THC in the rat. Neuropharmacology (1978) 0.81
Glutamatergic signaling by mesolimbic dopamine neurons in the nucleus accumbens. J Neurosci (2010) 2.53
Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J Neurosci (2010) 2.20
DAncing past the DAT at a DA synapse. Trends Neurosci (2004) 2.00
Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists. Bioorg Med Chem (2005) 1.93
Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity. Mol Pharmacol (2010) 1.86
Pregnenolone can protect the brain from cannabis intoxication. Science (2014) 1.85
A lipid pathway for ligand binding is necessary for a cannabinoid G protein-coupled receptor. J Biol Chem (2010) 1.59
An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region. J Med Chem (2003) 1.43
Activation of ATP-sensitive K+ (K(ATP)) channels by H2O2 underlies glutamate-dependent inhibition of striatal dopamine release. Proc Natl Acad Sci U S A (2003) 1.41
Endogenous hydrogen peroxide regulates the excitability of midbrain dopamine neurons via ATP-sensitive potassium channels. J Neurosci (2005) 1.33
Glutamate-dependent inhibition of dopamine release in striatum is mediated by a new diffusible messenger, H2O2. J Neurosci (2003) 1.33
N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol Pharmacol (2002) 1.28
CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity. Mol Pharmacol (2012) 1.26
Structural mimicry in class A G protein-coupled receptor rotamer toggle switches: the importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation. J Biol Chem (2004) 1.26
(-)-7'-Isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. Mol Pharmacol (2005) 1.24
Mutation studies of Ser7.39 and Ser2.60 in the human CB1 cannabinoid receptor: evidence for a serine-induced bend in CB1 transmembrane helix 7. Mol Pharmacol (2007) 1.24
Partial mitochondrial inhibition causes striatal dopamine release suppression and medium spiny neuron depolarization via H2O2 elevation, not ATP depletion. J Neurosci (2005) 1.23
Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation. Chem Biol (2008) 1.22
Mitochondria are the source of hydrogen peroxide for dynamic brain-cell signaling. J Neurosci (2009) 1.21
Mobilization of calcium from intracellular stores facilitates somatodendritic dopamine release. J Neurosci (2009) 1.19
Dopaminergic modulation of tracer coupling in a ganglion-amacrine cell network. Vis Neurosci (2007) 1.16
Cell-autonomous alteration of dopaminergic transmission by wild type and mutant (DeltaE) TorsinA in transgenic mice. Neurobiol Dis (2010) 1.14
Helix 8 Leu in the CB1 cannabinoid receptor contributes to selective signal transduction mechanisms. J Biol Chem (2007) 1.13
Lipids, lipid rafts and caveolae: their importance for GPCR signaling and their centrality to the endocannabinoid system. Life Sci (2005) 1.11
Palmitoylation and membrane cholesterol stabilize μ-opioid receptor homodimerization and G protein coupling. BMC Cell Biol (2012) 1.10
Adamantyl cannabinoids: a novel class of cannabinergic ligands. J Med Chem (2005) 1.09
3-Indolyl-1-naphthylmethanes: new cannabimimetic indoles provide evidence for aromatic stacking interactions with the CB(1) cannabinoid receptor. Bioorg Med Chem (2003) 1.06
Endocannabinoid tone versus constitutive activity of cannabinoid receptors. Br J Pharmacol (2011) 1.05
Cysteine 2.59(89) in the second transmembrane domain of human CB2 receptor is accessible within the ligand binding crevice: evidence for possible CB2 deviation from a rhodopsin template. Mol Pharmacol (2005) 1.01
Brain edema induced by in vitro ischemia: causal factors and neuroprotection. J Neurochem (2003) 1.01
Limited regulation of somatodendritic dopamine release by voltage-sensitive Ca channels contrasted with strong regulation of axonal dopamine release. J Neurochem (2006) 1.00
Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry (2011) 1.00
AMPA receptor-dependent H2O2 generation in striatal medium spiny neurons but not dopamine axons: one source of a retrograde signal that can inhibit dopamine release. J Neurophysiol (2008) 0.99
Residues accessible in the binding-site crevice of transmembrane helix 6 of the CB2 cannabinoid receptor. Biochemistry (2008) 0.97
Conformational memories and the endocannabinoid binding site at the cannabinoid CB1 receptor. J Med Chem (2002) 0.97
H2O2 signaling in the nigrostriatal dopamine pathway via ATP-sensitive potassium channels: issues and answers. Antioxid Redox Signal (2007) 0.94
NMDA receptor activation mediates hydrogen peroxide-induced pathophysiology in rat hippocampal slices. J Neurophysiol (2002) 0.92
Allosteric modulation of a cannabinoid G protein-coupled receptor: binding site elucidation and relationship to G protein signaling. J Biol Chem (2013) 0.91
Dysregulation of striatal dopamine release in a mouse model of dystonia. J Neurochem (2010) 0.91
Opposing regulation of dopaminergic activity and exploratory motor behavior by forebrain and brainstem cholinergic circuits. Nat Commun (2012) 0.90
A critical role for a tyrosine residue in the cannabinoid receptors for ligand recognition. Biochem Pharmacol (2002) 0.89
Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry (2013) 0.88
Regulation of postsynaptic Ca2+ influx in hippocampal CA1 pyramidal neurons via extracellular carbonic anhydrase. J Neurosci (2007) 0.88
Monitoring axonal and somatodendritic dopamine release using fast-scan cyclic voltammetry in brain slices. Methods Mol Biol (2013) 0.88
Conformational memories with variable bond angles. J Comput Chem (2008) 0.87
TRPM2 channels are required for NMDA-induced burst firing and contribute to H(2)O(2)-dependent modulation in substantia nigra pars reticulata GABAergic neurons. J Neurosci (2013) 0.86
Synaptic regulation of somatodendritic dopamine release by glutamate and GABA differs between substantia nigra and ventral tegmental area. J Neurochem (2002) 0.86
Modulation of somatodendritic dopamine release by endogenous H(2)O(2): susceptibility in substantia nigra but resistance in VTA. J Neurophysiol (2002) 0.85
Opioid receptors: toward separation of analgesic from undesirable effects. Trends Biochem Sci (2013) 0.84
GEC1-kappa opioid receptor binding involves hydrophobic interactions: GEC1 has chaperone-like effect. J Biol Chem (2008) 0.84
Subsecond regulation of striatal dopamine release by pre-synaptic KATP channels. J Neurochem (2011) 0.84
Regulation of Substantia Nigra Pars Reticulata GABAergic Neuron Activity by H₂O₂ via Flufenamic Acid-Sensitive Channels and K(ATP) Channels. Front Syst Neurosci (2011) 0.83
The glial antioxidant network and neuronal ascorbate: protective yet permissive for H(2)O(2) signaling. Neuron Glia Biol (2004) 0.83
Crucial positively charged residues for ligand activation of the GPR35 receptor. J Biol Chem (2013) 0.82
Endogenous lipid activated G protein-coupled receptors: emerging structural features from crystallography and molecular dynamics simulations. Chem Phys Lipids (2013) 0.81
Molecular dynamics simulations of the endocannabinoid N-arachidonoylethanolamine (anandamide) in a phospholipid bilayer: probing structure and dynamics. J Med Chem (2005) 0.81
Chromenopyrazoles: non-psychoactive and selective CB₁ cannabinoid agonists with peripheral antinociceptive properties. ChemMedChem (2012) 0.81
Parameterization of Org27569: an allosteric modulator of the cannabinoid CB1 G protein-coupled receptor. J Comput Chem (2011) 0.80
Classification of H₂O₂as a neuromodulator that regulates striatal dopamine release on a subsecond time scale. ACS Chem Neurosci (2012) 0.80
Cannabinoid CB1 receptor recognition of endocannabinoids via the lipid bilayer: molecular dynamics simulations of CB1 transmembrane helix 6 and anandamide in a phospholipid bilayer. J Comput Aided Mol Des (2006) 0.80
Lipid bilayer molecular dynamics study of lipid-derived agonists of the putative cannabinoid receptor, GPR55. Chem Phys Lipids (2010) 0.79
Inhibition of milk ingestion and growth after administration of a neutral cannabinoid CB1 receptor antagonist on the first postnatal day in the mouse. Pediatr Res (2007) 0.79
Cannabinoid CB(1) receptor ligand binding and function examined through mutagenesis studies of F200 and S383. Eur J Pharmacol (2010) 0.79
Differential calcium dependence of axonal versus somatodendritic dopamine release, with characteristics of both in the ventral tegmental area. Front Syst Neurosci (2011) 0.79
Novel insights into CB1 cannabinoid receptor signaling: a key interaction identified between the extracellular-3 loop and transmembrane helix 2. J Pharmacol Exp Ther (2013) 0.78
SKF-83566, a D1-dopamine receptor antagonist, inhibits the dopamine transporter. J Neurochem (2011) 0.78
Global fold of human cannabinoid type 2 receptor probed by solid-state 13C-, 15N-MAS NMR and molecular dynamics simulations. Proteins (2013) 0.78
Ascorbate distribution during hibernation is independent of ascorbate redox state. Free Radic Biol Med (2004) 0.78
Synthesis and pharmacology of 1-methoxy analogs of CP-47,497. Bioorg Med Chem (2010) 0.76
CB2-selective cannabinoid receptor ligands: synthesis, pharmacological evaluation, and molecular modeling investigation of 1,8-Naphthyridin-2(1H)-one-3-carboxamides. J Med Chem (2014) 0.76
Probing the carboxyester side chain in controlled deactivation (-)-δ(8)-tetrahydrocannabinols. J Med Chem (2014) 0.76
Striatal dopamine release regulation by the cholinergic properties of the smokeless tobacco, gutkha. ACS Chem Neurosci (2015) 0.75
Analogs of JHU75528, a PET ligand for imaging of cerebral cannabinoid receptors (CB1): development of ligands with optimized lipophilicity and binding affinity. Eur J Med Chem (2008) 0.75